KAILERA THERAPEUTICS INC
KLRANASDAQ🏆 #1602 by market capEarnings Aug 12US Equity
$18.87▼ $0.11 (−0.58%)
🌅 Pre-market$19.76▲ 4.72%Regular close · extended-hours price shown1h—
24h▼ 0.6%
7d▲ 3.8%
14d▲ 12.1%
30d▼ 5.5%
1y—
🏦Market Cap
$2.44B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
45
Weak
Trading Snapshot
- Day Range
- $18.69 – $19.02
- 52-Week Range
- $16.39 – $28.23
- Volume
- $2.66B
- Avg Volume
- $2.72B
- Shares Outstanding
- 129.6M
- Next Earnings
- Sep 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $284M
- Last Q Revenue
- $71M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own KLRA
- ✓High-growth profile — revenue up +38.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 76% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$284M▲ +38.9% YoY
Gross Margin (TTM)
75.6%▲ +3.3% YoY
Operating Income (TTM)
$70M▲ +38.9% YoY
Free Cash Flow (TTM)
$42M▲ +38.9% YoY
About KAILERA THERAPEUTICS INC
Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
45/100
Analyst Ratings
ⓘConsensus
Buy
12 analysts
Strong Buy5
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026
